Linifanib (ABT 869) is an oral tyrosine kinase inhibitor with antineoplasic activity. As a dual inhibitor, Linifanib, is being tested on several different cancers.
Molecular Spectra
No Data Available
Click here to submit data
References
• Cheng, A., et al.: J. Med. Chem., 53, 4502 (2010)
• Haddley, K., et al.: Drugs of the Future, 35, 106 (2010)